Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma.
نویسندگان
چکیده
1). If these lesions were at the level of the RPE, one would expect themtobevisualizedonFAFimaging.However, theywere completely silent on FAF imaging, suggesting that they may be located deeper than the RPE, at the level of the choriocapillaris.Wedistinguished 3 types of lesions basedon theirmultimodal imaging characteristics in APMPPE. Type 1 lesions seem to be located at the level of the choriocapillaris and are transient. Type 2 and 3 lesions are at the level of the RPE and are permanent. Thepigmented lesionswere distributed along the choroidal vasculature on AO imaging (Figure 2). They may correspond topigment-ladenmacrophagesor accumulationof pigment granules and may indicate a secondary reaction at the levelof theRPEinducedbyan inflammatoryprocessat the level of thechoroidalvasculature.Their sizeandshapewerenotconsistent with RPE cells. Acute posterior multifocal placoid pigment epitheliopathy is characterized by prominent RPE changes, but the permanent RPE damage (type 2 and 3 lesions) may be secondary to an acute transient choroidal inflammatory process (type 1 lesions).
منابع مشابه
Role of Vismodegib in the Management of Advanced Periocular Basal Cell Carcinoma.
BACKGROUND Vismodegib is the first selective hedgehog pathway inhibitor approved to treat locally advanced and metastatic basal cell carcinoma (BCC). Limited information is available concerning its role in managing advanced BCC around the eye. METHODS The medical literature was searched for cases of nonsyndromic periocular BCC treated with vismodegib. Clinical information was abstracted and a...
متن کاملVismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases
Basal cell carcinoma (BCC) is the most common periocular skin cancer and can lead to significant morbidity. We assess the effectiveness of vismodegib, a first-in-class Hedgehog signaling pathway inhibitor, in the management of periocular and orbital BCCs based on clinical response, tolerability, and orbital content preservation. All patients with periocular or orbital BCCs who met criteria for ...
متن کاملVismodegib for periocular and orbital basal cell carcinoma.
IMPORTANCE Basal cell carcinoma (BCC) represents 90% of malignant eyelid tumors and is locally invasive and destructive, if left untreated. OBJECTIVE To assess the feasibility of using vismodegib for periocular and orbital BCC based on its efficacy and tolerability. DESIGN, SETTING, AND PARTICIPANTS In this prospective observational case series, consecutive patients with periocular or orbit...
متن کاملPeriocular Basal Cell Carcinoma Predictors for Recurrence and Infiltration of the Orbit
PURPOSE To present the proportion of patients with periocular basal cell carcinoma (BCC) who underwent orbital exenteration and to evaluate the significance of the risk factors. DESIGN Retrospective, comparative, interventional case series. METHODS Data of all patients with BCC between 2008 and 2014 were reviewed for patient demographics, previous treatment options, tumor localization, and ...
متن کاملGranulation tissue masquerading as basal cell carcinoma after treatment with vismodegib
BCC: Basal cell carcinoma INTRODUCTION The case of a 65-year-oldwomanwith an advanced, ulcerated biopsy-proven basal cell carcinoma (BCC) located on the left side of her upper back is reviewed. She was treated with vismodegib with only mild clinical improvement. Pathologic analysis of subsequent surgical resection found only granulation tissue with no evidence of residual tumor. It is important...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- JAMA ophthalmology
دوره 131 10 شماره
صفحات -
تاریخ انتشار 2013